Putnam Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Putnam Investments’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-18,795	Closed	-$1.27M	–	1259
2017 Q1	$1.27M	Sell	18,795 -66,788	-78%	-$5.09M	﹤0.01%	957
2016 Q4	$6.02M	Sell	85,583 -442	-0.5%	-$31.4K	0.01%	516
2016 Q3	$6.1M	Buy	86,025 +2,936	+4%	+$187K	0.01%	506
2016 Q2	$4.06M	Buy	83,089 +18,209	+28%	+$1.18M	0.01%	719
2016 Q1	$4.11M	Sell	64,880 -9,627	-13%	-$630K	0.01%	713
2015 Q4	$8.36M	Buy	74,507 +9,627	+15%	+$963K	0.02%	507
2015 Q3	$6.25M	Hold	64,880	–	–	0.01%	594
2015 Q2	$6.64M	Buy	64,880 +200	+0.3%	+$15.5K	0.01%	615
2015 Q1	$4.02M	Hold	64,680	–	–	0.01%	840
2014 Q4	$2.84M	Hold	64,680	–	–	0.01%	921
2014 Q3	$3.66M	Sell	64,680 -200	-0.3%	-$10.1K	0.01%	867
2014 Q2	$2.91M	Hold	64,880	–	–	0.01%	937
2014 Q1	$3.17M	Buy	+64,880	New	+$3.34M	0.01%	929

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Putnam Investments's RARE Position: Q2 2017 in Review

Putnam Investments sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2017, closing a stake of 18,795 shares — an estimated $1.27M sold.

Putnam Investments first reported a position in RARE in Q1 2014 and held it in 13 quarters. The position peaked at $8.36M in Q4 2015. 158 funds tracked by Wall St. Rank hold RARE as of Q2 2017.

Putnam Investments reported no remaining Ultragenyx Pharmaceutical position as of Q2 2017 after selling out during the quarter.
Putnam Investments sold 18,795 Ultragenyx Pharmaceutical shares in Q2 2017, an estimated $1.27M.
Putnam Investments first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 13 quarters.
Putnam Investments's Ultragenyx Pharmaceutical position peaked at $8.36M in Q4 2015.
158 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2017.

Based on Putnam Investments's 13F filing for Q2 2017, filed 14 Aug 2017.